Novartis AG Form 6-K Summary: Full Year 2010
Business Context and Reporting Period
This Form 6-K, dated January 27, 2011, reports the audited financial results for Novartis AG for the fiscal year ended December 31, 2010. The reporting period covers the full year 2010 and the fourth quarter (Q4) 2010. A significant corporate event during this period was the acquisition of a 77% majority stake in Alcon, Inc. on August 25, 2010, which resulted in the consolidation of Alcon's financial results. The company also announced a definitive agreement to merge with Alcon to achieve 100% ownership, expected to close in the first half of 2011.
Key Financial Metrics
| Metric | FY 2010 (USD) | FY 2009 (USD) | Change (%) | Q4 2010 (USD) | Q4 2009 (USD) | Change (%) |
|---|---|---|---|---|---|---|
| Net Sales | 50.6 billion | 44.3 billion | +14% (+14% cc) | 14.2 billion | 12.9 billion | +10% (+11% cc) |
| Operating Income | 11.5 billion | 10.0 billion | +15% (+17% cc) | 2.5 billion | 2.6 billion | -6% (-3% cc) |
| Core Operating Income | 14.0 billion | 11.4 billion | +22% (+24% cc) | 3.2 billion | 3.2 billion | -1% (+2% cc) |
| Net Income | 10.0 billion | 8.5 billion | +18% (+20% cc) | 2.3 billion | 2.3 billion | -2% (+2% cc) |
| Earnings Per Share (EPS) | $4.28 | $3.70 | +16% | $0.95 | $1.01 | -6% |
| Core EPS | $5.15 | $4.50 | +14% | $1.14 | $1.26 | -10% |
| Free Cash Flow (before dividends) | 12.3 billion | 9.4 billion | +31% | 4.2 billion | 3.3 billion | +25% |
| Net Debt | 14.9 billion | (3.5 billion liquidity) | N/A | N/A | N/A | N/A |
Note: "cc" denotes constant currency. Net debt increased significantly due to the Alcon acquisition financing.
Material Changes vs. Prior Period
- Revenue Growth: Full-year sales grew 14% (14% constant currency), driven by volume expansion across all divisions and the consolidation of Alcon (contributing $2.4 billion). Recently launched products accounted for 21% of net sales ($10.4 billion).
- Profitability: Operating income rose 15%, with core operating income margin improving by 1.9 percentage points to 27.7%. This improvement was driven by productivity initiatives, partially offset by price erosion and currency headwinds.
- Q4 Volatility: Q4 operating income declined 6% year-over-year. This was primarily due to the absence of $1.0 billion in A(H1N1) pandemic flu vaccine sales recorded in Q4 2009, which were not repeated in 2010. Additionally, Q4 included one-off charges of $789 million, including inventory revaluation for Alcon and restructuring costs.
- Balance Sheet Shift: The company moved from a net cash position in 2009 to a net debt position of $14.9 billion in 2010, reflecting the $28.3 billion cash outflow to acquire the additional 52% stake in Alcon.
Guidance, Outlook, and Risks
- 2011 Outlook: Management expects group constant currency sales growth to be around the double-digit mark. Pharmaceuticals sales growth is projected in the low- to mid-single digits due to price reductions and generic competition (e.g., Femara patent expiry in June 2011, Diovan in Europe in February 2011). Sandoz is expected to grow at a mid-single-digit rate.
- Alcon Merger: The company anticipates completing the 100% merger with Alcon in the first half of 2011. This will add a fifth division and is expected to generate synergies. Full-year 2011 will include approximately $2.0 billion in amortization of intangible assets related to the Alcon acquisition.
- Innovation Pipeline: The company reported 13 major approvals and 16 major submissions in 2010. Key products include Gilenya (multiple sclerosis), Tasigna (chronic myeloid leukemia), and Lucentis (diabetic macular edema).
- Risks and Contingencies:
- Legal Proceedings: Ongoing litigation includes product liability cases for Zometa/Aredia (osteonecrosis of the jaw) and Zelnorm (cardiovascular injuries). A $422.5 million settlement regarding off-label marketing of Trileptal and five other products was reached in 2010.
- Regulatory: Risks include government price cuts, patent expiries, and potential delays in regulatory approvals for pipeline products.
- Integration: Risks associated with the integration of Alcon and the realization of expected synergies.
Key Facts for Investor Verification
- Alcon Consolidation Impact: Verify the specific contribution of Alcon to Q4 and full-year results, noting that Alcon was only consolidated from August 25, 2010, and that Q4 results include significant one-time inventory revaluation charges ($372 million) related to the change in majority ownership.
- A(H1N1) Vaccine Variance: Confirm the impact of the non-recurring A(H1N1) pandemic flu vaccine sales ($1.3 billion in FY 2010, $1.0 billion in Q4 2009) on the Vaccines and Diagnostics division's comparability.
- Core vs. GAAP Reconciliation: Review the reconciliation of IFRS results to "Core" results, which excludes amortization, impairments, and restructuring costs. Core operating income margin (27.7%) is significantly higher than reported operating income margin (22.8%).
- Patent Expiries: Monitor the impact of upcoming patent expiries for key products like Femara (US, June 2011) and Diovan (Europe, February 2011) on 2011 revenue guidance.
- Debt Levels: Assess the sustainability of the new net debt position ($14.9 billion) and the company's ability to service this debt while maintaining dividend growth (proposed CHF 2.20 per share for 2010).